0.42
-6.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Caribou Biosciences
From its filings with the US Securities and Exchange Commission
Caribou Biosciences is based in Berkeley, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CRBU. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $11.2m and a net loss of $148.1m. At that date it held total assets of $175.4m and shareholders' equity of $122.2m. By region, United States accounted for 84.9%, followed by Rest of world at 15.1%.
We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPR hybrid RNA-DNA, or “chRDNA,” pronounced “chardonnay”) genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.
Our allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”) -T (“CAR-T”) cell therapy product candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. Our allogeneic CAR-T cell therapy product candidates in clinical development are directed at CD19 and B cell maturation antigen (“BCMA”), established cell surface targets against which autologous CAR-T cell therapeutics have already demonstrated clinical proof of concept. We use our chRDNA technology to armor our cell therapy product candidates through genome-editing strategies, such as checkpoint disruption and immune cloaking, to enhance activity against hematologic malignancies.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jul 2021
- Employees
- 97
- Website
- cariboubio.com ↗
- Head office
- 2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Andrew GuggenhimeIndependent Chairman of the Board$269,162
- Dr. Rachel HaurwitzPresident, Chief Executive Officer, Co-Founder, Director, since 2021$4.2m
- Mr. Sriram RyaliChief Financial Officer
- Mr. Tim KellyChief Technology Officer$1.9m
- Dr. Steven KannerChief Scientific Officer$1.6m
- Dr. Tina AlbertsonChief Medical Officer
- Ms. Ruhi KhanChief Business Officer$1.0m
- Ms. Barbara McClungChief Legal Officer, Corporate Secretary$1.6m
- Dr. Scott BraunsteinIndependent Director$232,081
- Mr. David JohnsonIndependent Director$221,667
- Dr. Dara Richardson-HeronIndependent Director$222,815
- Dr. Natalie SacksIndependent Director$228,358
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 56
- Social
- 51
- Governance
- 57
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Caribou Biosciences' CRISPR hybrid RNA-DNA platform enables precise genome editing for cell therapies.
- The company's pipeline includes CB-010, CB-011, CB-012, and CB-020 for hematologic malignancies.
- Caribou's off-the-shelf CAR-T and CAR-NK therapies target solid tumors and blood cancers.
Weaknesses
- Caribou has only 97 employees, which may limit research and development capacity.
- The company's IPO in 2021 may indicate limited financial resources for expansion.
- Caribou's focus on CRISPR therapies requires significant capital investment.
Opportunities
- The growing demand for CRISPR-based therapies in the Health Care sector presents opportunities.
- Caribou's CB-010 is in clinical stages for treating CD19-positive malignancies.
- Expanding into new markets for allogeneic cell therapies could increase market share.
Threats
- Competition from other biotechnology firms in the CRISPR space is increasing.
- Regulatory hurdles for CRISPR therapies may delay product approvals.
- High costs associated with CRISPR therapy development could impact profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.